Micah Rosenfield, MD
Family Medicine · West Valley City, UTNPI 1194757336
Payments from drug & device makers
Across 192 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$290
- Novo Nordisk$267
- Boehringer Ingelheim$240
- Merck$229
- Medtronic$221
- Pfizer$213
- plus $2K from 31 others
What the payments were for
- Food & beverage$2,972100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 22 | $290 |
| Novo Nordisk | 20 | $267 |
| Boehringer Ingelheim | 12 | $240 |
| Merck | 19 | $229 |
| Medtronic | 2 | $221 |
| Pfizer | 21 | $213 |
| GSK | 14 | $211 |
| Amgen | 11 | $184 |
| Sanofi-aventis U.S. LLC | 11 | $128 |
| AstraZeneca | 8 | $116 |
| Johnson & Johnson | 7 | $116 |
| AbbVie(2 entities) | 6 | $101 |
| Idorsia Pharmaceuticals US Inc | 4 | $72 |
| Gilead | 4 | $71 |
| Dynavax Technologies Corporation | 3 | $48 |
| Irhythm Technologies, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $37 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $30 |
| Exact Sciences | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $28 |
| Alkermes, Inc. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $20 |
| Bayer | 1 | $19 |
| Indivior Inc. | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Strongbridge US Inc. | 1 | $18 |
| Sobi, Inc | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
| Corium, LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Lucid Diagnostics Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,972 in reported general payments places this provider in the 75th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 80 | $99,844 |
| OzempicSemaglutide | 41 | $67,189 |
| EliquisApixaban | 47 | $38,798 |
| FarxigaDapagliflozin Propanediol | 32 | $25,145 |
| TrulicityDulaglutide | 19 | $22,531 |
| XareltoRivaroxaban | 22 | $20,633 |
| MyrbetriqMirabegron | 18 | $14,747 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $13,356 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $9,657 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,914 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,385 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,593 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,606 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,411 |
| Rosuvastatin Calcium | 219 | $2,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $240 | $105,43791 claims |
| Novo NordiskOzempic | $267 | $67,18941 claims |
| PfizerEliquis | $213 | $38,79847 claims |
| GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta | $211 | $29,65652 claims |
| AstraZenecaFarxiga, Symbicort | $116 | $28,55647 claims |
| Lilly USA, LLCTrulicity | $290 | $22,53119 claims |
| Johnson & JohnsonXarelto | $116 | $20,63322 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $14,74718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 928 family medicine providers in Utah.
Other family medicine in West Valley City
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
- Katie JulienSouth Jordan$7.1M
- Scott EricksonBountiful$3.7M
- John RichardsSouth Jordan$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.